ResearchMoz

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2013

GlobalData
Published Date » 2013-11-30
No. Of Pages » 159
 GlobalData's Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals Q3 2013 report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&A) and financing in the pharmaceutical and healthcare market. The report provides detailed information on partnerships, licensing agreements, M&As, equity/debt offerings, private equity and venture financing transactions recorded in the pharmaceutical and healthcare industry in Q3 2013. The report presents detailed comparative data on the number of deals and their value in the last five quarters, categorized into deal types, segments, and geographies. The report also provides information on the top venture capital and advisory firms in the pharmaceutical and...
Table of Contents

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 7
1.2 List of Figures 11

2 Pharmaceuticals & Healthcare, Global, Deal Summary, Q3 2013 15
2.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, Q3 2013 15
2.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, Q3 2013 17
2.3 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, Q3 2013 18
2.4 Pharmaceuticals & Healthcare, Global, Top Deals, Q3 2013 19
2.4.1 Shoppers Drug Mart Receives Ontario Court Approval for Its Acquisition by Loblaw for US$11.93 Billion 19
2.4.2 Amgen Completes Tender Offer to Acquire Onyx Pharma for up To US$10.4 Billion 21
2.4.3 Community Health Systems to Acquire Health Management Associates for up to US$7.6 Billion 22
2.4.4 Fresenius to Acquire 43 Hospitals from Rhon-Klinikum for US$4.1 Billion 23
2.4.5 Tenet Healthcare Prices Private Placement of Notes Due 2022 for US$2.8 Billion 24

3 Pharmaceuticals & Healthcare, Global, Deals Summary, by Type 25
3.1 Pharmaceuticals & Healthcare, Global, M&A, Q3 2013 25
3.1.1 Top M&A Deals in Q3 2013 26
3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, Q3 2012 - Q3 2013 27
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Q3 2013 29
3.2.1 Top Initial Public Offerings in Q3 2013 31
3.2.2 Top Secondary Offerings in Q3 2013 31
3.2.3 Top PIPE Deals in Q3 2013 31
3.2.4 Pharmaceuticals & Healthcare, Global, Top IPOs Share Performance, Q3 2012-Q3 2013 32
3.2.5 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Q3 2012 - Q3 2013 33
3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, Q3 2013 35
3.3.1 Top Venture Financing Deals in Q3 2013 36
3.3.2 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q3 2013 37
3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q3 2013 38
3.3.4 Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, Q3 2012 - Q3 2013 39
3.3.5 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Last Four Quarters 41
3.3.6 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q3 2012 - Q3 2013 43
3.4 Pharmaceuticals & Healthcare, Global, Private Equity Deals, Q3 2013 44
3.4.1 Top Private Equity Deals in Q3 2013 45
3.4.2 Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Q3 2012 - Q3 2013 46

4 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q3 2013 48
4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q3 2013 48
4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Q3 2012 - Q3 2013 50
4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2013 52
4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Values, Q3 2013 54
4.3.2 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q3 2013 54
4.3.3 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payments, Q3 2013 55
4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2012 - Q3 2013 56
4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, Q3 2012 - Q3 2013 58
4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$ m), Q3 2012 - Q3 2013 59
4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2012 - Q3 2013 61

5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q3 2013 63
5.1 Pharmaceutical & Healthcare, Global, Licensing Agreements, Q3 2013 63
5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2012 - Q3 2013 65
5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Value, Q3 2013 67
5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, Q3 2013 67
5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q3 2013 68
5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q3 2012 - Q3 2013 69
5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payments Vs Milestone Payments (US$ m), Q3 2012 - Q3 2013 71
5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q3 2012 - Q3 2013 73
5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q3 2012 - Q3 2013 74
5.7 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payments Vs Milestone Payments (US$ m), Q3 2012 - Q3 2013 76

6 Pharmaceuticals & Healthcare, Global, M&A Financial Analysis 78
6.1 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value versus Median Deal Value, Q3 2012 - Q3 2013 78
6.2 Pharmaceuticals& Healthcare, Global Acquisitions, Average Price Earnings of Acquired Companies, Q3 2012 - Q3 2013 80
6.3 Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q3 2012 - Q3 2013 82
6.4 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q3 2012 - Q3 2013 84
6.5 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Market Price Per Share, Q3 2012 - Q3 2013 86
6.6 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Book Value Per Share, Q3 2012 - Q3 2013 88
6.7 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q3 2012 - Q3 2013 90

7 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 92
7.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, Q3 2013 92
7.1.1 Oncology - Deals of the Quarter 94
7.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, Q3 2013 96
7.2.1 Central Nervous System - Deals of the Quarter 98
7.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, Q3 2013 101
7.3.1 Infectious Disease - Deals of the Quarter 103
7.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, Q3 2013 105
7.4.1 Immunology - Deals of the Quarter 107
7.5 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, Q3 2013 108
7.5.1 Metabolic Disorders - Deals of the Quarter 110
7.6 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, Q3 2013 112
7.6.1 Cardiovascular - Deals of the Quarter 114
7.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, Q3 2013 116
7.7.1 Gastrointestinal - Deals of the Quarter 118
7.8 Pharmaceuticals & Healthcare, Global, Dermatology Deals, Q3 2013 119
7.8.1 Dermatology - Deals of the Quarter 121
7.9 Pharmaceuticals & Healthcare, Global, Respiratory Deals, Q3 2013 122
7.9.1 Respiratory - Deals of the Quarter 124
7.10 Pharmaceuticals & Healthcare, Global, Ophthalmology Deals, Q3 2013 126
7.10.1 Ophthalmology - Deals of the Quarter 128

8 Deal Summary by Geography 130
8.1 Pharmaceuticals & Healthcare, North America Region, Deals, Q3 2013 130
8.1.1 North America - Deals of the Quarter 132
8.2 Pharmaceuticals & Healthcare, Europe Region, Deals, Q3 2013 135
8.2.1 Europe - Deals of the Quarter 137
8.3 Pharmaceuticals & Healthcare, Asia-Pacific, Deals, Q3 2013 139
8.3.1 Asia-Pacific - Deals of the Quarter 141
8.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, Q3 2013 144
8.4.1 Rest of the World - Deals of the Quarter 146

9 Pharmaceuticals & Healthcare, Global, Top Advisors 148
9.1 Pharmaceuticals & Healthcare, Global Top Financial Advisors, M&A, Last One Year 148
9.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Last One Year 150

10 Appendix 152

11 Further Information 156
11.1 Methodology 156
11.2 About GlobalData 157
11.3 Disclosure information 158
11.4 Disclaimer 158

List of Tables


Table 1: Pharmaceuticals & Healthcare, Global, Deal Summary, Number of Deals and Deal Values (US$m), Q3 2012 - Q3 2013 16
Table 2: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), Q3 2013 19
Table 3: Pharmaceuticals & Healthcare, Global, Top Deals, Q3 2013 19
Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 26
Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, Q3 2013 26
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, , Q3 2012 - Q3 2013 28
Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$m), Q3 2012 - Q3 2013 30
Table 8: Pharmaceuticals & Healthcare, Global, Top Initial Public Offering Deals, Q3 2013 31
Table 9: Pharmaceuticals & Healthcare, Global, Top Secondary Offering Deals, Q3 2013 31
Table 10: Pharmaceuticals & Healthcare, Global, Top PIPE Deals, Q3 2013 31
Table 11: Pharmaceuticals & Healthcare, Global, Top IPOs Share Performance, Q3 2012-Q3 2013 32
Table 12: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$m), Q3 2012 - Q3 2013 34
Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 36
Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Capital Deals, Q3 2013 36
Table 15: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number of Deals and Deal Values (%), Q3 2013 38
Table 16: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q3 2012 - Q3 2013 40
Table 17: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q4 2012 - Q3 2013 42
Table 18: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q3 2012 - Q3 2013 43
Table 19: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 45
Table 20: Pharmaceuticals & Healthcare, Global, Top Private Equity Deals, Q3 2013 45
Table 21: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q3 2012 - Q3 2013 47
Table 22: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 49
Table 23: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 51
Table 24: Pharmaceuticals & Healthcare, Partnership Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2012 - Q3 2013 53
Table 25: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2013 54
Table 26: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q3 2013 54
Table 27: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, Q3 2013 55
Table 28: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q3 2012 - Q3 2013 57
Table 29: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q3 2012 - Q3 2013 60
Table 30: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Values (US$ m), Q3 2012 - Q3 2013 62
Table 31: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deal Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 64
Table 32: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2012 - Q3 2013 66
Table 33: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Deal Values, Q3 2013 67
Table 34: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Upfront Payment, Q3 2013 67
Table 35: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Milestone Payment, Q3 2013 68
Table 36: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 70
Table 37: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment (US$ m), Q3 2012 - Q3 2013 72
Table 38: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q3 2012 - Q3 2013 75
Table 39: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment and Deal Values (US$ m), Q3 2012 - Q3 2013 77
Table 40: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value vs Median Deal Value, (US$m), Q3 2012 - Q3 2013 79
Table 41: Pharmaceuticals & Healthcare, Global Acquisitions, Average P/E of Acquired Companies, Q3 2012 - Q3 2013 81
Table 42: Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q3 2012 - Q3 2013 83
Table 43: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Operating Profit, Q3 2012 - Q3 2013 85
Table 44: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Market Price Per Share, Q3 2012 - Q3 2013 87
Table 45: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Book Value Per Share, Q3 2012 - Q3 2013 89
Table 46: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q3 2012 - Q3 2013 91
Table 47: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 93
Table 48: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 97
Table 49: Pharmaceuticals & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 102
Table 50: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 106
Table 51: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 109
Table 52: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 113
Table 53: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 117
Table 54: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 120
Table 55: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 123
Table 56: Pharmaceuticals & Healthcare, Global, Ophthalmology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 127
Table 57: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 131
Table 58: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 136
Table 59: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 140
Table 60: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 145
Table 61: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q4 2012 - Q3 2013 149
Table 62: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q4 2012 - Q3 2013 151
Table 63: Pharmaceuticals & Healthcare, Deals’ Key Financials, Global Acquisition Deals, Q3 2012-Q3 2013 152

List of Figures


Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$m), Q3 2012 - Q3 2013 15
Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), Q3 2013 17
Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), Q3 2013 18
Figure 4: Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$m), Q3 2012 - Q3 2013 25
Figure 5: Pharmaceuticals & Healthcare, Global, M&As, by Therapy Area, Number of Deals and Deal Values (US$m), by Therapy Area, Q3 2012 - Q3 2013 27
Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 29
Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$m), , Q3 2012 - Q3 2013 33
Figure 8: Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 35
Figure 9: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%), Q3 2013 37
Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Deal Values (%), Q3 2013 38
Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q3 2012 - Q3 2013 39
Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q4 2012 - Q3 2013 41
Figure 13: Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 44
Figure 14: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q3 2012 - Q3 2013 46
Figure 15: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 48
Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 50
Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront & Milestone Payment and Deal Values (US$ m), Q3 2012 - Q3 2013 52
Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q3 2012 - Q3 2013 56
Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q3 2012 - Q3 2013 58
Figure 20: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q3 2012 - Q3 2013 59
Figure 21: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payment and Deal Values (US$ m), Q3 2012 - Q3 2013 61
Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 63
Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2012 - Q3 2013 65
Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 69
Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2012 - Q3 2013 71
Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Number Of Deals, Q3 2012 - Q3 2013 73
Figure 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Deal Values (US$ m), Q3 2012 - Q3 2013 74
Figure 28: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2012 - Q3 2013 76
Figure 29: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value vs Median Deal Value, (US$m), Q3 2012 - Q3 2013 78
Figure 30: Pharmaceuticals & Healthcare, Global Acquisitions, Average P/E of Acquired Companies, Q3 2012 - Q3 2013 80
Figure 31: Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q3 2012 - Q3 2013 82
Figure 32: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q3 2012 - Q3 2013 84
Figure 33: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Market Price Per Share, Q3 2012 - Q3 2013 86
Figure 34: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Book Value Per Share, Q3 2012 - Q3 2013 88
Figure 35: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q3 2012 - Q3 2013 90
Figure 36: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 92
Figure 37: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 96
Figure 38: Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 101
Figure 39: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 105
Figure 40: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 108
Figure 41: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 112
Figure 42: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 116
Figure 43: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 119
Figure 44: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 122
Figure 45: Pharmaceuticals & Healthcare, Global, Ophthalmology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 126
Figure 46: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 130
Figure 47: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 135
Figure 48: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 139
Figure 49: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 144
Figure 50: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q4 2012 - Q3 2013 148
Figure 51: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q4 2012 - Q3 2013 150

Upcoming Reports:

Biobutanol Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
With the increase in population our demand for energy is also increasing day by day, hence we are always looking for some alternate source of energy that can fulfill our energy demands. Biobutanol which is a renewable source of energy can help us in achieving this energy security. Biobutanol also known as butyl alcohol is a 4 carbon chained non polar molecule similar to that of gasoline. Despite being from an alcoholic group its energy content is much closer to that of gasoline and hence can be used as the substitute of gasoline as a cleaner fuel. It can be produced by fermentation...
EPharmacies Market - Global Industry Size, Market Share, Trends, Analysis, And Forecasts 2012 - 2018
By - Transparency Market Research
The global market for ePharmacies is projected to reach USD 51.75 billion by the end of 2017 owing to the increasing number of tech-savvy people and rising demand for prescription drugs. The ePharmacies meeting the regulatory standards set by the government and following ethical business practices are likely to emerge as safe, affordable, and accessible source of prescription drugs in the near future. The present scenario reflects higher penetration of the ePharmacy industry in developed countries as compared to the developing market. This is mainly because of the increasing use of...
Poland: sulfonamides market
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the sulfonamides market in Poland and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the sulfonamides market in Poland, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an elaborate overview of the...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Hitachi Readies New Suite of Driving Systems
Oct 16, 2014  
Japan’s Hitachi Automotive Systems is all set to unveil a line of innovative autonomous driving technologies as the trend of high-tech and automotive electronics takes the industry by storm. The suite of technologies were unveiled in northern Japan last week and included features such as no-hands self-parking, vehicle stability control in electric automobiles, precrash braking, and...
Canadas Agreement on Waste-Water Treatment Boosts Indias PM Pet Clean Ganga Project
Oct 16, 2014  
In 2008, Canada and India adopted a bilateral science and technology collaboration agreement for Scientific and Technological Cooperation.  The pet Clean Ganga project led by the Indian Prime Minister Narendra Modi has received a confident boost with an agreement earlier on Wednesday. The agreement is all about cleaning up the most heavily used river in the world between Canada...
China Sends Experimental Ebola Drugs to Aid Workers, to Increase Supply if Found Effective
Oct 16, 2014  
An experimental Ebola drug has been sent to Africa for use by Chinese aid worker by a Chinese drug manufacturer. The company is plans to undertake clinical trials of the drug to combat the deadly Ebola outbreak in West Africa that has claimed more than 4000 lives so far. Several thousand doses of the drug JK-05, manufactured by Sihuan Pharmaceutical Holdings Group Ltd, have been...
Broccoli Based Chemical Gives Hope For Treating Autism
Oct 15, 2014  
According to the inferences derived from a small scale clinical trial, the chemical that is extracted from the sprouts of broccoli possess certain anti-cancerous properties. Moreover, this chemical may be able to even treat behavioral symptoms in those suffering from autism spectrum disorders. This research study was carried out by the scientists of Johns Hopkins University School of Medicine...
Toyota China to Recall Crown Sedans Due to Leaking Brake Fluid Issue
Oct 15, 2014  
Joining the global wave of automobile recalls, Toyota has announced its decision to recall 93,700 cars from the Chinese market to fix an issue regarding leaking brake fluid, Chinese quality watchdog has informed.  Tianjin FAW Toyota Motor Co, the Chinese subsidiary of Toyota Motor Corp., will recall the Crown model sedans manufactured by it between 1st December 2009 and 14th June 2012....